Global ADME Toxicology Testing Market by Technology (Cell Culture, High Throughput, Molecular Imaging, OMICS Technology), By Application (Systemic Toxicity, Renal Toxicity, Hepatotoxicity, Neurotoxicity, Other Applications), By Method (Cellular Assay, Biochemical Assay, In Silica, Ex-vivo) By Region and Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Estimate 2023-2032

Report Overview

The ADME Toxicology Testing Market size is expected to be worth around USD 20,394.8 million by 2032 from USD 6,685 million in 2022, growing at a CAGR(compound annual growth rate) of 11.8 during the forecast period 2023 to 2032.

A growing amount of drug molecules are failing during clinical trials, leading to a loss of time and investment in drug discovery time and growth key factors. This has led to increased investment in developing new technologies for toxic testing. This will help increase the market definition over the next decade.

Global ADME Toxicology Testing Market Scope:

Technology Analysis

There is a growing demand for innovative therapies to treat a variety of conditions. Technology segments in almost every industry are expected to offer lucrative opportunities during the estimated period. The most critical step in obtaining the desired results is the analysis of processed and screened data. This must be done with precision. The major factor of chemical public libraries has been developed that aid in reporting results and setting the highest standards.

With a market largest share of over 40.0%, cell culture Technology was the leading segment in 2021. Because of their visible results and ability to test with small volumes, FIP assays are the most popular cell-based assays. Ultra ADME toxicology testing, the most recent Technology in the field, allows for enlarged output in a shorter time. Several companies are currently in transition, moving from 2-D cell culture to 3-D.

Three-dimensional cells have more life-like properties than two-dimensional cells. They can also be used to test the environment and other manipulations that aid in drug discovery activities and design. There are several steps that can be taken to increase market growth, including the progress of software and hardware to fully automate testing and the expansion of chemical libraries to identify chemical identity hits.

Method Analysis

With a market share of approximately 45.0% in 2021, cell assays were the top net profit generator in ADME toxicology testing. The segment growth is aided by issues such as accuracy, detail, and natural results from cell assays. For drug candidates, cell-based assays that measure physiological parameters can be used to bridge the gap between clinic and laboratory. These assays don’t necessarily replace clinical trials, but they do make human research less risky. They also reduce the no. of animals needed for research. This is an important aspect of the growing sensitivity to the rights of animals.

Application Analysis

ADME toxicology testing can be used to determine the severity of human reactions to drug interaction molecules. There are several examples: systemic toxicity, neurotoxicity, and renal toxicity. Systemic toxicology was the top-earning segment in 2021, thanks to an increase in toxicology studies of the circulatory system. It is the most dangerous cause of toxic reactions in human bodies.

In 2021, systemic toxicology held about 70% of the market and will continue to hold that position throughout the estimated period. The systemic circulation of a drug design molecule is the preferred method of distribution. However, this is one of the main causes of toxic reactions that can cause multiple organ failures. This segment holds a large share of the market.

Key Market Segments:

Technology

• Cell Culture
• High Throughput
• Molecular Imaging
• OMICS Technology

Application

• Systemic Toxicity
• Renal Toxicity
• Hepatotoxicity
• Neurotoxicity
• Other Applications

Method

• Cellular Assay
• Biochemical Assay
• In Silica
• Ex-vivo

Market Dynamics:

ADME toxicology testing can conduct various chemical, genetic interactions, and pharmacological tests. This aids in the drug discovery process. Control software, liquid handling devices, and other detectors are used to quickly identify active compounds and biomolecular interactions. These techniques require skilled expertise and software capable of handling and storing multiple data sets at a rapid rate. This could hinder the market growth.

ADME toxicology testing is performed stage during drug development and design to avoid any late-stage failures and ensure systematic evaluation to avoid investment loss. To meet regulatory standards, most companies use both GLP and non-GLP testing procedures. To ensure the integrity and accuracy of data stored and obtained, regulatory bodies are pushing for tighter quality control standards.

Market and innovation direction will be affected by regulatory changes made by governing bodies like the U.S. FDA. Some FDA departments have requested that companies conduct ADME toxicology testing of animals with the same disease as humans to establish a clear distinction between the real-time results from close situations and those of normal animals.

Regional Market Analysis:

North America was the country with the highest share, more than 47.1%, in 2021. Content screening emerged as a significant contributor. The reason for this is due to technological advancements in the field, especially in the U.S. Cell culture drug discovery techniques have gained popularity with companies looking to enter the market with new drugs. Asia Pacific will grow rapidly in the coming years because of increased research into new pharmaceutical molecules and new technologies that improve the quality of medicine supplied. Japan and China are two key contributors to the market’s segmental growth rate.

Regions and Key Countries Covered in the Report:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Russia
  • Spain
  • Rest of Europe
• APAC
  • China
  • Japan
  • South Korea
  • India
  • Rest of Asia-Pacific
• Latin America
  • Brazil
  • Argentina
  • Rest of South America
• MEA
  • GCC
  • South Africa
  • Israel
  • Rest of the Middle East & Africa

Market Share & Key Players Analysis:

Accelrys Inc., Agilent Technologies, Inc., Albany Molecular Research Inc., Beckman Coulter Inc., Catalent Inc., AbbVie, Actelion Pharmaceuticals, Amgen, Bristol-Myers Squibb, And Cipla, are some of the significant shares of players in this market. Companies are being forced to use accurate toxicity testing techniques to reduce development costs and time wasted on failing stages of drug development because of the fiercely competitive landscape from other manufacturers. The following are leading key market players, among others.

Market Key Prominent Players:

• Accelrys Inc.
• Agilent Technologies Inc. (USA)
• Albany Molecular Research Inc. (USA)
• Bio-Rad Laboratories, Inc.
• Beckman Coulter, Inc. (USA)
• BioIVT LLC.
• BioreclamationIVT LLC (USA)
• Cerep SA (France)
• CompuDrug International Inc. (USA)
• Cyprotex PLC. (UK)
• Dassault Systemes Biovia Corp. (USA)
• Eurofins ADME BIOANALYSES SAS (France)
• Galapagos NV (Belgium)
• Molecular Discovery Ltd. (UK)
• Optivia Biotechnology (USA)
• Pharmaron Inc. (USA)
• Catalent, Inc.
• Charles River Laboratories International Inc.
• Cipla AbbVie
• CeeTox, Inc.
• Covance Inc. (USA)
• Gentronix Limited
• Eurofins Scientific (Luxembourg)
• MultiCASE, Inc. (USA)
• EVOTEC AG
• Laboratory Corporation of America Holdings
• Actelion Pharmaceuticals
• Amgen
• SGS S.A.
• Accelrys, Inc.
• Perkinelmer Inc. (USA)
• Thermo Fisher Scientific, Inc.
• Xceleron, Inc.
• Other Key Players

---

For the ADME-Toxicology Testing Market research study, the following years have been considered to estimate the market size: